Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer

Table 1 Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics n (%)

Clinicopathological characteristics	n	HER2		χ2	P value
		Positive	Negative
Sex				1.2736	0.2591
Male	132	27 (20.45)	105 (79.55)
Female	65	9 (13.85)	56 (86.15)
Age (yr)				1.3056	0.2532
< 60	88	13 (14.77)	75 (85.23)
≥ 60	109	23 (21.10)	86 (78.90)
Tumor site1				0.0409	0.9798
Cardiac	31	6 (19.35)	25 (80.65)
Body	42	8 (19.05)	34 (80.96)
Pylorus	122	22 (18.03)	100 (81.97)
Lauren classification				6.5759	0.0103
Intestinal	63	18 (28.57)	45 (71.43)
Diffuse/mixed	134	18 (13.43)	116 (86.57)
Tumor differentiation				16.6003	< 0.0001
Well-differentiated	51	19 (37.25)	32 (62.75)
Poorly-differentiated	146	17 (11.64)	129 (88.36)
TNM classification				0.6754	0.879
I	13	2 (15.38)	11 (84.62)
II	46	7 (15.22)	39 (84.78)
III	98	20 (20.41)	78 (79.59)
IV	40	7 (17.50)	33 (82.50)

¹Two remnant samples were not included. HER2: Human epidermal growth factor receptor 2.

Table 2 Immunochemistry-fluorescence in situ hybridization concordance n (%)

FISH	IHC				Total
	3+	2+	1+	0
Positive	14	10	7	0	31 (15.74)
Negative	5	15	21	125	166 (84.26)
Total	19 (9.64)	25 (12.69)	28 (14.21)	125 (63.45)	197

IHC: Immunochemistry; FISH: Fluorescence in-situ hybridization.

Table 3 Correlation of human epidermal growth factor recept-or 2 expression with tumor node metastasis staging n (%)

Clinicopathological characteristics	n	HER2		χ2	P value
		Positive	Negative
T				0.5782	0.4470
T1-T2	26	6 (23.08)	20 (76.92)
T3-T4	171	29 (16.96)	142 (84.04)
N				4.6274	0.2012
N0	55	8 (14.55)	47 (85.45)
N1	83	20 (24.10)	63 (75.90)
N2	33	5 (15.15)	28 (84.85)
N3	26	2 (7.69)	24 (92.31)
M				0.0000	1.0000
M0	185	33 (17.84)	152 (82.16)
M1	12	2 (16.67)	10 (83.33)

HER2: Human epidermal growth factor receptor 2.

Table 4 Relationship of different clinicopathological characteristics and prognosis

Clinicopathological characteristics	HER2 positive			HER2 negative			χ2	P value
	Median survival time (mo)	1-year survival rate	2-year survival rate	Median survival time (mo)	1-year survival rate	2-year survival rate
Sex
Male	20	74.34%	50.18%	20	83.96%	69.00%	2.2591	0.1328
Female	10	100.00%	50.00%	16.5	74.50%	51.79%	0.0182	0.8927
Age (yr)
≤ 60	23	100.00%	57.14%	20	80.54%	61.81%	0.0104	0.9186
> 60	15	67.55%	49.13%	18	80.62%	64.35%	1.6356	0.2009
Tumor site
Cardiac	19	66.67%	50.00%	15	69.51%	49.15%	0.0494	0.8242
Body	16.5	62.50%	62.50%	14	67.80%	44.07%	0.1561	0.6927
Pylorus	17	85.56%	46.67%	20	87.00%	73.25%	2.3295	0.1269
Lauren classification
Intestinal	17	84.85%	50.91%	27	89.17%	76.53%	2.3604	0.1244
Diffues/mixed	14	67.53%	49.24%	16.5	76.99%	57.24%	0.1907	0.6623
Tumor differentiation
Well-differentiated	18.5	84.42%	50.65%	27.5	96.00%	86.89%	6.2701	0.0123
Poorly-differentiated	14	67.88%	49.49	17	76.56%	56.71%	0.0988	0.7532
TNM classification
I and II stages	18.5	68.57%	57.14%	21.5	93.60%	79.20%	2.9813	0.0842
III and IV stages	17	82.59%	45.88%	16.5	73.32%	54.12%	0.0263	0.8711
T
T1-T	17	66.67%	66.67%	28	100.00%	92.31%	3.4587	0.0629
T3-T4	15	91.30%	46.99%	17	77.47%	58.26%	0.2953	0.5869
N
N0	14	68.57%	51.43%	21	90.46%	74.98%	2.0667	0.1505
N1-N3	18.5	79.19%	49.49%	17	75.73%	57.27%	0.0531	0.8177
M
M0	17	78.67%	54.69%	20	84.41%	66.01%	0.7842	0.3757
M1	11.5	50.00%	0.00%	5	0.00%	0.00%	0.5900	0.4424

HER2: Human epidermal growth factor receptor 2.